Zucara Therapeutics Announces Second and Final Closing of US$25 Million Series B Financing – T1D Fund Joins Financing Syndicate – – Proceeds to Fund Remainder of Phase 2a ‘ZONE’ Trial and Nonclinical Development of a Once-Weekly Version of ZT-01 – Toronto, Canada, May 1, 2025 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes […]
Zucara Therapeutics Announces Strategic Investment from Sanofi as Part of US$20 Million Series B Financing – Sanofi and Existing Investor, Perceptive Advisors’ PXV Fund I, Invested a combined US$20 million as part of the Financing – – Sanofi to Receive Exclusive Right of First Negotiation – – Proceeds to Fund Remainder of Phase 2a ‘ZONE’ […]
Zucara Therapeutics Doses First Patient in Phase 2a ‘ZONE’ Trial – ZONE study to evaluate the effect of ZT-01 on preventing nighttime hypoglycemia in people with Type 1 diabetes – – ZT-01 has the potential to become the first therapeutic to prevent nocturnal hypoglycemia, a condition for which there are currently no available therapies – […]
– Award to provide US$2 million to support Zucara’s planned Phase 2a ZONE trial, with first patient dosing expected in Q3 2023 – Toronto, Canada, June 15, 2023 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes-focused life sciences company developing the first once-daily therapeutic to prevent hypoglycemia (low blood glucose levels) in people […]
– First patient dosing expected in Q3 2023 – – ZONE study to assess ZT-01’s ability to prevent night-time hypoglycemia, a condition for which there are currently no available therapies – Toronto, Canada, April 19, 2023 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes-focused life sciences company developing the first once-daily therapeutic to […]
– Achieves development milestones required to complete Series A financing – – Plans to file Phase 2 investigational new drug (IND) application by year end, with first patient dosing in Q1 2023 – Toronto, Canada, September 19, 2022 – Zucara Therapeutics Inc., (“Zucara” or the “Company”) a diabetes life sciences company developing the first once-daily […]
– Proof-of-Concept Trial Confirms ZT-01’s Mechanism of Action in Restoring Glucagon Release in Patients with Type 1 Diabetes – – First-in-Class ZT-01 has the Potential to Become the First Therapeutic to Prevent Hypoglycemia in Patients with Insulin-Dependent Diabetes – Toronto, Canada, June 22, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the […]
Zucara Therapeutics Secures Additional Funding from GlycoNet and Mitacs for the Development of ZT-01 – Second grants from GlycoNet and Mitacs will support ZT-01’s advancement to the clinic for the treatment of insulin-induced hypoglycemia in people with Type 2 diabetes – Toronto, Canada, May 2, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company […]
Zucara Therapeutics Announces Publication of Preclinical Study Demonstrating ZT-01’s Ability to Restore Glucagon Release in Type 1 Diabetes – ZT-01 restored glucagon secretion, and reduced the frequency and severity of hypoglycemia in preclinical model of insulin-induced hypoglycemia – Toronto, Canada, February 8, 2022 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first […]
Zucara Therapeutics Doses First Patients in Phase 1b Trial of ZT-01 – Proof-of-Concept Trial to Evaluate the Effect of ZT-01 on Insulin-Induced Hypoglycemia in Patients with Type 1 Diabetes – Toronto, Canada, July 27, 2021 – Zucara Therapeutics Inc., a diabetes life sciences company developing the first once-daily therapeutic to prevent insulin-induced hypoglycemia (low blood […]